Corbus Pharmaceuticals (CRBP)

• Market cap: $205M
• 1 day: -1.1%
• 5 days: 6.47%
• 1 month: -36.05%
• 3 months: 26.79%
• 6 months: 54.43%
• Year to date: -2.91%
• 1 year: -27.3%
• 5 years: -67.8%
• 10 years: -77.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 28